These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2198583)

  • 1. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
    Kleinerman ES; Jaffe N
    Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal MTP-PE.
    Gano JB; Kleinerman ES
    J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposome-enhanced tumour therapy in canine mammary gland tumours.
    Teske E; Rutteman GR
    Tijdschr Diergeneeskd; 1993 Mar; 118 Suppl 1():32S-33S. PubMed ID: 8480312
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
    MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE
    J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal MTP-PE: a promising new biologic response modifier.
    Gano JB; Kleinerman ES
    Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
    Mori K; Ando K; Heymann D
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
    Ando K; Mori K; Corradini N; Redini F; Heymann D
    Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status.
    Frost H
    Biotherapy; 1992; 4(3):199-204. PubMed ID: 1599803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
    Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.